Tesamorelin/Ipamorelin Blend

Tesamorelin and ipamorelin blend with 15 mg total content per vial. Individual component amounts are not specified in the supplier catalog. For in-vitro research only.

• The first constituent is the 1-44 amide with a trans-3-hexenoyl group on Tyr1, a change that made it resistant to dipeptidyl aminopeptidase IV and slowed its degradation in rat, dog and human plasma. [1]
• The second constituent is the pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2, which released growth hormone from primary rat pituitary cells with an EC50 of 1.3 nmol/l. [2]
• Antagonist profiling put the pentapeptide response at a GHRP-like receptor rather than the growth hormone releasing hormone receptor, so the two constituents are characterised through different pathways. [2]
• Detection work lists the larger growth hormone releasing hormone analogues as separate analytes with their own in-vitro metabolites, so each constituent of a mixture has to be identified in its own right. [3]

Compound

Tesamorelin/Ipamorelin Blend

Purity

99.10% (HPLC)

Identity

Confirmed by MS

Appearance

White lyophilate

Presentation

15 mg

Catalog / lot

RV-0022 / RV-24-0022-1

For research use only. Not for human or veterinary use. Not a drug, food, cosmetic, or supplement.

Review the laboratory, lot identifier, and reported results in this document. Keep the lot identifier with your research records.